scispace - formally typeset
Search or ask a question
Author

Marvah Mahmood

Bio: Marvah Mahmood is an academic researcher from Government College University, Faisalabad. The author has contributed to research in topics: Epitope & Vaccination. The author has an hindex of 1, co-authored 1 publications receiving 5 citations.
Topics: Epitope, Vaccination, Adjuvant, Immunogenicity

Papers
More filters
Journal ArticleDOI
TL;DR: In this article, a multi-epitope vaccine (MEV) was designed to combat infections of M. pneumoniae top five highly antigenic proteins using a combination of immunological techniques and molecular docking.

9 citations


Cited by
More filters
Journal ArticleDOI
16 Jun 2021-Vaccine
TL;DR: In this paper, the authors combined core proteomics with a subtractive proteomics pipeline to identify suitable antigenic proteins for the construction of a multi-epitope vaccine (MEV) against human-infecting Schistosoma species.

26 citations

Journal ArticleDOI
03 Oct 2021-Biology
TL;DR: In this article, the authors used core proteomics, immuno-informatics, and subtractive proteomics approaches to identify the best antigenic candidates for the development of a multi-epitope-based vaccine (MEBV).
Abstract: Chlamydia trachomatis, a Gram-negative bacterium that infects the rectum, urethra, congenital sites, and columnar epithelium of the cervix. It is a major cause of preventable blindness, ectopic pregnancy, and bacterial sexually transmitted infections worldwide. There is currently no licensed multi-epitope vaccination available for this pathogen. This study used core proteomics, immuno-informatics, and subtractive proteomics approaches to identify the best antigenic candidates for the development of a multi-epitope-based vaccine (MEBV). These approaches resulted in six vaccine candidates: Type III secretion system translocon subunit CopD2, SctW family type III secretion system gatekeeper subunit CopN, SycD/LcrH family type III secretion system chaperone Scc2, CT847 family type III secretion system effector, hypothetical protein CTDEC_0668, and CHLPN 76kDa-like protein. A variety of immuno-informatics tools were used to predict B and T cell epitopes from vaccine candidate proteins. An in silico vaccine was developed using carefully selected epitopes (11 CTL, 2 HTL & 10 LBL) and then docked with the MHC molecules (MHC I & MHC II) and human TLR4. The vaccine was coupled with Cholera toxin subunit B (CTB) adjuvant to boost the immune response. Molecular dynamics (MD) simulations, molecular docking, and MMGBSA analysis were carried out to analyze the molecular interactions and binding affinity of MEBV with TLR4 and MHC molecules. To achieve the highest level of vaccine protein expression, the MEBV was cloned and reverse-translated in Escherichia coli. The highest level of expression was achieved, and a CAI score of 0.97 was reported. Further experimental validation of the MEBV is required to prove its efficacy. The vaccine developed will be useful in preventing infections caused by C. trachomatis.

18 citations

Journal ArticleDOI
26 Sep 2021-Vaccine
TL;DR: In this article, a multiple-epitope vaccine (MEV) was designed to battle against C. perfringens infection, which is a highly versatile bacteria of livestock and humans, causing enteritis (a common foodborne illness in humans), enterotoxaemia (in which toxins are formed in the intestine which damage and destroy organs, i.e., the brain), and gangrene (wound infection).

11 citations

Journal ArticleDOI
TL;DR: The detailed in silico analysis concludes that the proposed vaccine will induce a strong immune response against MPXV infection, making it a promising target for additional experimental trials.
Abstract: Abstract Monkeypox is a viral zoonotic disease that is caused by the monkeypox virus (MPXV) and is mainly transmitted to human through close contact with an infected person, animal, or fomites which is contaminated by the virus. In the present research work, reverse vaccinology and several other bioinformatics and immunoinformatics tools were utilized to design multi-epitopes-based vaccine against MPXV by exploring three probable antigenic extracellular proteins: cupin domain-containing protein, ABC transporter ATP-binding protein and DUF192 domain-containing protein. Both cellular and humoral immunity induction were the main concerning qualities of the vaccine construct, hence from selected proteins both B and T-cells epitopes were predicted. Antigenicity, allergenicity, toxicity, and water solubility of the predicted epitopes were assessed and only probable antigenic, non-allergic, non-toxic and good water-soluble epitopes were used in the multi-epitopes vaccine construct. The developed vaccine was found to be potentially effective against MPXV and to be highly immunogenic, cytokine-producing, antigenic, non-toxic, non-allergenic, and stable. Additionally, to increase stability and expression efficiency in the host E. coli, disulfide engineering, codon adaptation, and in silico cloning were employed. Molecular docking and other biophysical approaches were utilized to evaluate the binding mode and dynamic behavior of the vaccine construct with TLR-2, TLR-4, and TLR-8. The outcomes of the immune simulation demonstrated that both B and T cells responded more strongly to the vaccination component. The detailed in silico analysis concludes that the proposed vaccine will induce a strong immune response against MPXV infection, making it a promising target for additional experimental trials. Communicated by Ramaswamy H. Sarma

11 citations

Journal ArticleDOI
22 Nov 2021-Vaccine
TL;DR: Wang et al. as mentioned in this paper combined immunological approaches with molecular docking approaches for three highly antigenic proteins to design vaccines against Klebsiella aerogenes, and the synthesis of the B-cell, T-cell (CTL and HTL) and IFNγ epitopes of the targeted proteins was performed and most conserved epitopes were chosen for future research studies.

7 citations